Co-Diagnostics Inc (CODX)

[Opti Mist]

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test. This is an important tool because these viruses have similar symptoms but require different treatment approaches.

I wonder when they submitted this for FDA approval and how that compares to when CODX submitted. I am trying to guess when we can expect approval.

Opti